Drug Treatment of Cancers
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: 25 September 2025 | Viewed by 3504
Special Issue Editor
2. Houston Methodist Research Institute, Houston, TX 77030, USA
Interests: transplant oncology; liver cancer; cholangiocarcinoma; targeted therapy; immunotherapy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cancer remains one of the leading causes of morbidity and mortality worldwide, encompassing a diverse group of diseases characterized by uncontrolled cell growth. Among these, various cancers— including, but not limited to, breast, lung, colorectal, and liver cancers—present significant therapeutic challenges. While surgical interventions, such as tumor resection or organ transplantation, can be curative in select cases, only a small percentage of patients are eligible. Systemic treatments, including chemotherapy regimens like gemcitabine and cisplatin, have improved overall survival for many cancer types. The integration of immunotherapy, such as immune checkpoint inhibitors (e.g., pembrolizumab and nivolumab), has further revolutionized treatment outcomes. Recently, the Food and Drug Administration (FDA) approved several targeted and immunotherapy treatments. Additionally, advancements in monitoring tests, including liquid biopsies, circulating tumor DNA (ctDNA) analysis, and imaging techniques, have enhanced early detection, treatment response assessment, and disease progression monitoring.
This Special Issue will highlight the current state of drug treatments and monitoring tests for all cancers, emphasizing innovative therapeutic strategies and diagnostic advancements.
Dr. Abdullah Esmail
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer
- oncology
- chemotherapy
- immunotherapy
- targeted therapy
- precision medicine
- liquid biopsy
- circulating tumor DNA (ctDNA)
- imaging
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
